Loading
CO
Clovis Oncology, Inc. Stock: price and insider trades · United States
Clovis Oncology, Inc.: what insiders have been doing
Headquartered in Wilmington, United States, Clovis Oncology, Inc. belongs to the Healthcare & Pharma sector and traces its origins to 2009. Filings by its managers are published through SEC (Form 4). No insider at Clovis Oncology, Inc. has published a filing in the past twelve months. The most recent one dates from 3 November 2022.
Our records for Clovis Oncology, Inc. go back to 2017, with 14 purchases and 293 sales on the open market in total.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
675
Thresholds
n/a
Buy Volume
€550,683
14 ops. · all time
Sell Volume
€7M
293 ops. · all time
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
RevenueUS$128.1M
Net income-US$227.8M-177.8% margin
Last declaration on 3 November 2022
Declarations675 total
1,675 shares@ US$0.9829Common StockSEC:0000899243-22-034897:1
4,625 sharesCommon StockSEC:0000899243-22-034897:2
2,006 shares@ US$0.9829Common StockSEC:0000899243-22-034897:3
1,908 shares@ US$0.9829Common StockSEC:0000899243-22-034890:1
4,625 sharesCommon StockSEC:0000899243-22-034890:2
2,353 shares@ US$0.9829Common StockSEC:0000899243-22-034890:3
2,513 shares@ US$0.983Common StockSEC:0000899243-22-034892:1
4,625 sharesCommon StockSEC:0000899243-22-034892:2
2,066 shares@ US$0.983Common StockSEC:0000899243-22-034892:3
788 shares@ US$0.9829Common StockSEC:0000899243-22-034896:1
1,812 sharesCommon StockSEC:0000899243-22-034896:2
915 shares@ US$0.9829Common StockSEC:0000899243-22-034896:3
181 sharesCommon StockSEC:0000899243-22-034896:4
63 shares@ US$0.9827Common StockSEC:0000899243-22-034896:5
2,595 shares@ US$0.9829Common StockSEC:0000899243-22-034898:1
4,625 sharesCommon StockSEC:0000899243-22-034898:2
2,135 shares@ US$0.9829Common StockSEC:0000899243-22-034898:3
3,749 sharesCommon StockSEC:0000899243-22-034890:0
5,623 sharesCommon StockSEC:0000899243-22-034898:0
3,749 sharesCommon StockSEC:0000899243-22-034897:0
5,623 sharesCommon StockSEC:0000899243-22-034892:0
1,562 sharesCommon StockSEC:0000899243-22-034896:0
6 shares@ US$1.29Common StockSEC:0000899243-22-032655:1
15 sharesCommon StockSEC:0000899243-22-032655:0
1,444 shares@ US$1.20Common StockSEC:0000899243-22-030419:1
25 of 675 declarations
About Clovis Oncology, Inc.
Clovis Oncology, Inc. was a U.S.-based biopharmaceutical company focused on oncology precision medicine and historically listed on the NASDAQ market in the United States. Founded in 2009 and long headquartered in Boulder, Colorado, the company built its business model around acquiring, developing, and commercializing anti-cancer therapies aimed at well-defined patient subgroups, often in combination with companion diagnostics. Its best-known commercial asset was Rubraca® (rucaparib), an oral PARP inhibitor used in specific oncology indications, including certain ovarian cancer settings and, at one point, metastatic castration-resistant prostate cancer. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1466301/000156459016013672/clvs-10k_20151231.htm?utm_source=openai))
From an industry perspective, Clovis belonged to the specialized biotech segment, where value creation depends on clinical differentiation, regulatory execution, and the ability to serve niche oncology populations. The company’s legacy footprint extended beyond the United States, with operations and additional offices in Europe, including Cambridge in the United Kingdom and Milan, Italy. That international setup reflected its ambition to develop and commercialize oncology assets across the U.S., Europe, and other markets. Its competitive set included other PARP inhibitor developers, targeted oncology biotechs, and larger pharmaceutical groups active in precision cancer care. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1466301/000156459016013672/clvs-10k_20151231.htm?utm_source=openai))
Read moreShow less
Clovis’s corporate trajectory is also defined by financial stress and restructuring. The company and certain subsidiaries filed voluntary Chapter 11 petitions in December 2022 in the U.S. Bankruptcy Court for the District of Delaware. The court later confirmed the company’s Third Amended Joint Chapter 11 Plan of Liquidation in June 2023, with an effective date of July 10, 2023. For equity investors, that is a critical point: the company’s public-market story is no longer one of normal growth execution, but of restructuring and asset disposition. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1466301/000119312522303179/d386858dex991.htm?utm_source=openai))
In analytical terms, Clovis was a classic high-risk oncology biotech: concentrated product exposure, heavy clinical and regulatory dependence, and significant financing vulnerability. The most recent material developments therefore center on bankruptcy proceedings and asset sales rather than product launches or commercial acceleration. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1466301/000119312523094018/d492602d8k.htm?utm_source=openai))
